Immunity and immunosuppression in experimental visceral leishmaniasis

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 4, 2004, Pages 615-623

  Goto, H ^a   Lindoso, J A L ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

Author keywords

Cytokines; Hamster; Immunosuppression; Mice; T cell; Visceral leishmaniasis

Indexed keywords

ANTIGEN; B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LEISHMANIA VACCINE; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; B LYMPHOCYTE; DISEASE MODEL; DISEASE PREDISPOSITION; GENE FUNCTION; HAMSTER; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; LEISHMANIA; MACROPHAGE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROTEIN SYNTHESIS; REVIEW; SKIN LEISHMANIASIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; VISCERAL LEISHMANIASIS;

ANIMALIA; CRICETINAE; PROTOZOA;

EID: 2442583468     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004000400020     Document Type: Review

References (60)

1. Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, Teixeira R & Johnson Jr WD (1986). New perspectives on a subclinical form of visceral leishmaniasis. Journal of Infectious Diseases, 154: 1003-1011.
2. Sacks D & Noben-Trauth N (2002). The immunology of susceptibility and resistance to Leishmania major in mice. Nature Reviews. Immunology, 2: 845-858.
3. Murray HW, Stern JJ, Welte K, Rubin BY, Carriero SM & Nathan CF (1987). Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin-2 and interferon-gamma. Journal of Immunology, 138: 2290-2297.
4. Rodrigues Jr V, Silva JS & Campos-Neto A (1992). Selective inability of spleen antigen presenting cells from Leishmania donovani infected hamsters to mediate specific T cell proliferation to parasite antigens. Parasite Immunology, 14: 49-58.
5. Skov CB & Twohy DW (1974). Cellular immunity to Leishmania donovani. I. The effect of T cell depletion on resistance to Leishmania donovani in mice. Journal of Immunology, 113: 2004-2011.
6. Rezai HR, Farrell J & Soulsby EL (1980). Immunological responses of Leishmania donovani infection in mice and significance of T cell resistance to experimental leishmaniasis. Clinical and Experimental Immunology, 40: 508-514.
7. + cells in experimental visceral leishmaniasis. Journal of Immunology, 140: 3971-3977.
8. McElrath MJ, Murray HW & Cohn ZA (1988). The dynamics of granuloma formation in experimental visceral leishmaniasis. Journal of Experimental Medicine, 167: 1927-1937.
9. Murray HW, Squires KE, Miralles GD, Stoeckle MY, Granger AM, Granelli-Piperno A & Bogdan C (1992). Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. Journal of Immunology, 148: 1858-1863.
10. Squires KE, Schreiber RD, McElrath MJ, Rubin BY, Anderson SL & Murray HW (1989). Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. Journal of Immunology, 143: 4244-4249.
11. Murray HW, Miralles GD, Stoeckle MY & McDermott DF (1993). Role and effect of IL-2 in experimental visceral leishmaniasis. Journal of Immunology, 151: 929-938.
12. Saha B, Basak SK & Roy S (1993). Immunobiological studies on experimental visceral leishmaniasis. III. Cytokine-mediated regulation of parasite replication. Scandinavian Journal of Immunology, 37: 155-158.
13. Kaye PM, Curry AJ & Blackwell JM (1991). Differential production of TH1-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. Journal of Immunology, 146: 2763-2770.
14. Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD & Murray HW (1994). Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infection and Immunity, 62: 1058-1063.
15. Satoskar A, Bluethmann H & Alexander J (1995). Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infection and Immunity, 63: 4894-4899.
16. Karp CL, el-Safi SH, Wynn TA, Satti MM, Kordofani AM, Hashim FA, Hag-Ali M, Neva FA, Nutman TB & Sacks DL (1993). In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. Journal of Clinical Investigation, 91: 1644-1648.
17. Melby PC, Yang YZ, Chang J & Zhao W (1998). Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infection and Immunity, 66: 18-27.
18. Murphy ML, Wille U, Villegas EN, Hunter CA & Farrell JP (2001). IL-10 mediates susceptibility to Leishmania donovani infection. European Journal of Immunology, 31: 2848-2856.
19. Murray HW, Lu CM, Mauze S, Freeman S, Moreira AL, Kaplan G & Coffman RL (2002). Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infection and Immunity, 70: 6284-6293.
20. Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X & Heinzel FP (2003). Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. Journal of Infectious Diseases, 188: 458-464.
21. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA & Sacks DL (2001). The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. Journal of Experimental Medicine, 194: 1497-1506.
22. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM & Sacks DL (2002). CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature, 420: 502-507.
23. Gorelik L, Constant S & Flavell RA (2002). Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. Journal of Experimental Medicine, 195: 1499-1505.
24. Murray HW & Hariprashad J (1995). Interleukin-12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. Journal of Experimental Medicine, 181: 387-391.
25. Taylor AP & Murray HW (1997). Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. Journal of Experimental Medicine, 185: 1231-1239.
26. Murray HW (1997). Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. Journal of Infectious Diseases, 175: 1477-1479.
27. Satoskar AR, Rodig S, Telford 3rd SR, Satoskar AA, Ghosh SK, von Lichtenberg F & David JR (2000). IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. European Journal of Immunology, 30: 834-839.
28. Wilson ME, Recker TJ, Rodriguez NE, Young BM, Burnell KK, Streit JA & Kline JN (2002). The TGF-beta response to Leishmania chagasi in the absence of IL-12. European Journal of Immunology, 32: 3556-3565.
29. Bunn-Moreno MM, Madeira ED, Miller K, Menezes JA & Campos-Nato A (1985). Hypergammaglobulinaemia in Leishmania donovani infected hamsters: possible association with a polyclonal activator of B cells with suppression of T cell function. Clinical and Experimental Immunology, 59: 427-434.
30. Galvao-Castro B, Sa Ferreira JA, Marzochi KF, Marzochi MC, Coutinho SG & Lambert PH (1984). Polyclonal B cell activation, circulating immune complexes and autoimmunity in human American visceral leishmaniasis. Clinical and Experimental Immunology, 56: 58-66.
31. Sacks DL, Scott PA, Asofsky R & Sher FA (1984). Cutaneous leishmaniasis in anti-IgM-treated mice: enhanced resistance due to functional depletion of a B cell-dependent T cell involved in the suppressor pathway. Journal of Immunology, 132: 2072-2077.
32. Hoerauf A, Solbach W, Lohoff M & Rollinghoff M (1994). The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice. International Immunology, 6: 1117-1124.
33. Hoerauf A, Rollinghoff M & Solbach W (1996). Co-transfer of B cells converts resistance into susceptibility in T cell-reconstituted, Leishmania major-resistant C.B-17 scid mice by a non-cognate mechanism. International Immunology, 8: 1569-1575.
34. Hoerauf A, Solbach W, Rollinghoff M & Gessner A (1995). Effect of IL-7 treatment on Leishmania major-infected BALB.Xid mice: enhanced lymphopoiesis with sustained lack of B1 cells and clinical aggravation of disease. International Immunology, 7: 1879-1884.
35. Smelt SC, Cotterell SE, Engwerda CR & Kaye PM (2000). B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. Journal of Immunology, 164: 3681-3688.
36. Kima PE, Constant SL, Hannum L, Comenares M, Lee KS, Haberman AM, Shlomchik MJ & McMahon-Pratt D (2000). Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. Journal of Experimental Medicine, 191: 1063-1067.
37. Kane MM & Mosser DM (2001). The role of IL-10 in promoting disease progression in leishmaniasis. Journal of Immunology, 166: 1141-1147.
38. Carvalho EM, Teixeira R & Johnson Jr WD (1981). Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infection and Immunity, 33: 498-502.
39. Basak SK, Saha B, Bhattacharya A & Roy S (1992). Immunobiological studies on experimental visceral leishmaniasis. II. Adherent cell-mediated down-regulation of delayed-type hypersensitivity response and up-regulation of B cell activation. European Journal of Immunology, 22: 2041-2045.
40. Lindoso JAL (2001). Apoptose na evolução da leishmaniose visceral experimental em hamster. Doctoral thesis, Disciplina de Alergia e Imunopatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
41. Vasconcellos RCS, Urago KP, Bunn-Moreno MM & Madeira ED (1996). Suppressor activity in Leishmania donovani-infected hamster serum: reversion by delipidated bovine serum albumin and role in cell cycle events. Brazilian Journal of Medical and Biological Research, 29: 615-622.
42. Nickol AD & Bonventre PF (1986). Immunosuppression associated with visceral leishmaniasis of hamsters. Parasite Immunology, 7: 439-449.
43. Blackwell JM & Ulczak OM (1984). Immunoregulation of genetically controlled acquired responses to Leishmania donovani infection in mice: demonstration and characterization of suppressor T cells in noncure mice. Infection and Immunity, 44: 97-102.
44. Murray HW, Carriero SM & Donelly DM (1986). Presence of a macrophage-mediated suppressor cell mechanism during cell-mediated immune response in experimental visceral leishmaniasis. Infection and Immunity 54: 487-493.
45. Reiner NE, Ng W & McMaster WR (1987). Parasite-accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products. Journal of Immunology, 138: 1926-1932.
46. Saha B, Das G, Vohra H, Ganguly NK & Mishra GC (1995). Macrophage-T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity. European Journal of Immunology, 25: 2492-2498.
47. Rodrigues Jr V, Silva JS & Campos-Neto A (1998). Transforming growth factor β and immunosuppression in experimental visceral leishmaniasis. Infection and Immunity, 66: 1233-1236.
48. Goto H, Gomes CMC, Monteiro HP, Corbett CEP & Gidlund M (1998). Insulin-like growth factor (IGF)-I is a growth promoting factor for Leishmania promastigotes and amastigotes. Proceedings of the National Academy of Sciences, USA, 95: 13211-13216.
49. Vendrame CMV, Carvalho MDT & Goto H (2002). Effect of insulin-like growth factor (IGF) I and II on the nitric oxide (NO) production by Leismania-infected macrophages. Revista do Instituto de Medicina Tropical de São Paulo, 44 (Suppl 12): 118 (Abstract).
50. Melby PC, Tryon W, Chandrasekar B & Freeman GL (1998). Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infection and Immunity, 66: 2135-2142.
51. Das G, Vohra H, Saha B, Agrewala JN & Mishra GC (1998). Leishmania donoveni infection of a susceptible host results in apoptosis of Th1-like cells: rescue of anti-leishmanial CMI by providing Th1-specific bystander costimulation. Microbiology and Immunology, 42: 795-801.
52. Murphy ML, Engwerda CR, McCrossen M & Kaye PM (1997). B7-2 blockade enhances T cell responses to Leishmania donovani. Journal of Immunology, 159: 4460-4466.
53. + T lymphocytes from Leishmania chagasi-infected mice increase cytokine production and mediate parasite killing after blockade of B7-1/CTLA-4 molecular pathway. Journal of Infectious Diseases, 178: 1847-1851.
54. Murphy ML, Cotterell SEJ, Gorak PMA, Engwerda CR & Kaye PM (1998). Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. Journal of Immunology, 161: 4153-4160.
55. Gomes NA, Gattass CR, Barreto-de Souza V, Wilson ME & DosReis GA (2000). TGF-β mediated CTLA-4 suppression of cellular immunity in murine kalaazar. Journal of Immunology, 164: 2001-2008.
56. Masteller EL, Chuang E, Mullen AC, Reiner SL & Thompson CB (2000). Structural analysis of CTLA-4 function in vivo. Journal of Immunology, 164: 5319-5327.
57. Gomes NA & DosReis GA (2001). The dual role of CTLA-4 in Leishmania infection. Trends in Parasitology, 17: 487-491.
58. + T-cell apoptosis and decreased Th1 cytokine production. Scandinavian Journal of Immunology, 49: 307-310.
59. Alexander CE, Kaye PM & Engwerda CR (2001). CD 95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice. European Journal of Immunology, 31: 1199-1210.
60. Moore K & Matlashewski G (1994). Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. Journal of Immunology, 152: 2930-2937.